The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies

Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option against COVID-19. Because rapidly emerging virus mutants are becoming the next major concern in the fight against the global pandemic, it is imperative that these therapeutic treatments provide coverage against ci...

Descripción completa

Detalles Bibliográficos
Autores principales: Copin, Richard, Baum, Alina, Wloga, Elzbieta, Pascal, Kristen E., Giordano, Stephanie, Fulton, Benjamin O., Zhou, Anbo, Negron, Nicole, Lanza, Kathryn, Chan, Newton, Coppola, Angel, Chiu, Joyce, Ni, Min, Wei, Yi, Atwal, Gurinder S., Hernandez, Annabel Romero, Saotome, Kei, Zhou, Yi, Franklin, Matthew C., Hooper, Andrea T., McCarthy, Shane, Hamon, Sara, Hamilton, Jennifer D., Staples, Hilary M., Alfson, Kendra, Carrion, Ricardo, Ali, Shazia, Norton, Thomas, Somersan-Karakaya, Selin, Sivapalasingam, Sumathi, Herman, Gary A., Weinreich, David M., Lipsich, Leah, Stahl, Neil, Murphy, Andrew J., Yancopoulos, George D., Kyratsous, Christos A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179113/
https://www.ncbi.nlm.nih.gov/pubmed/34161776
http://dx.doi.org/10.1016/j.cell.2021.06.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179113/
https://www.ncbi.nlm.nih.gov/pubmed/34161776
http://dx.doi.org/10.1016/j.cell.2021.06.002

Ejemplares similares